Inflamalps
Valais, CH · 1 known investors
Inflamalps is a biopharmaceutical company discovering anti-inflammatory and anti-microbial molecules, with its lead candidate INF101 targeting dry eye disease in ophthalmology. Since 2020 it has run a drug discovery program for novel anti-microbial molecules in partnership with academic and CRO partners across Europe and New Zealand.
BiotechMedical Devices